Clinical trials: Healthy Volunteers Type 2 Diabetes
Diabetes
Experimental Study to Validate the Modified Glucose Disposal Test
Evaluate the modified GDT as a measure of key metabolic characteristics in healthy subjects and those with type 2 diabetes mellitus
- Trial name
- NCT01152372
- Testing
- Insulin, glucose and staple isotopes
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
A SAD Study of ZT002 Injection in Healthy Participants
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.
- Trial name
- NCT06423872
- Testing
- ZT002
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in…
- Trial name
- NCT05579314
- Testing
- XW014
- Where
- 3 sites in United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences USA Co., Ltd.
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.
- Trial name
- NCT01042106
- Testing
- DSP-8658
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Type 2 Diabetes Mellitus
A Study of ZT002 in Healthy Participants
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.
- Trial name
- NCT05491421
- Testing
- ZT002
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- QL Biopharmaceutical Australia Pty Ltd
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Type 2 Diabetes Mellitus
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
This is a phase I, open-label, fixed-sequence study in healthy Chinese subjects, performed at a single study centre. Cohort A will assess the Pharmacokinetic (PK) profile of rongliflozin when administered alone and the…
- Trial name
- NCT05497674
- Testing
- Rongliflozin, Rifampin, Probenecid
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Type 2 Diabetes Mellitus
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00404963
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00882726
- Testing
- CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients)
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Type 2 Diabetes Mellitus
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis)…
- Trial name
- NCT01068717
- Testing
- Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
The DDI Study of SP2086 and Valsartan
The purpose of the study is to investigate the potential PK interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy male volunteers.
- Trial name
- NCT02817217
- Testing
- SP2086, Valsartan
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers
The purpose of this research study is to evaluate the effect of several daily doses of ketoconazole (a medication used to treat fungal infections like athlete's foot) on a single dose of GSK189075 (an experimental diabetes drug)…
- Trial name
- NCT00501397
- Testing
- ketoconazole, GSK189075
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
T2DM (Type 2 Diabetes Mellitus)
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single dose of HSK7653 tablets in healthy adult subjects, and to identify the metabolites of HSK7653 in healthy adult subjects
- Trial name
- NCT05983289
- Testing
- HSK7653
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Metabolic Syndrome, Type 2 Diabetes
Bed Rest, Alternate Daily Fasting and Incretin Effect
Bed rest produces insulin resistance in healthy volunteers. In this study the investigators aim to investigate the effect of 8 days bed rest on the incretin effect and how alternate daily fasting affects cognitive function and…
- Conditions
- Metabolic Syndrome, Type 2 Diabetes, Critical Illness
- Trial name
- NCT02134860
- Testing
- Bed rest, OGTT, IVGTT
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Type 2 Diabetes Mellitus
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults
A randomized, open-label, single dose, two-way crossover study to compare the pharmacokinetics and safety/tolerability of CKD-370 with D745 in healthy volunteers
- Trial name
- NCT03849495
- Testing
- CKD-370, D745
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients…
- Trial name
- NCT00633997
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis
Type 2 Diabetes Mellitus, Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06226727
- Testing
- BR1019, BR1019-1, BR1019-2
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type 2
A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components
This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin…
- Trial name
- NCT01780051
- Testing
- Repaglinide/Metformin combination, Repaglinide, Metformin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dalim BioTech Co., Ltd.
Healthy Volunteers, Diabetes Mellitus, Type 2
A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0472-0147, its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT04262661
- Testing
- NNC0472-0147, insulin glargine
- Where
- 2 sites in Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S